Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.

GlaxoSmithKline (GSK)

Status and phase: Withdrawn; Phase 1

Conditions: Healthy Subjects

Treatments: Drug: GW842166X

Study type: Interventional

Funder types: Industry

Identifiers

NCT00536497

CBA109358

Details and patient eligibility

About

GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. The purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of GW842166X in healthy male and female volunteers.

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body weight >50 Kg and BMI within the range 18.5-29.9 Kg/m2 inclusive.
• Healthy as judged by a responsible physician.

Exclusion criteria

• Positive pre-study urine screen for drugs of abuse or alcohol breath test.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)